id crelsevierbv:10.1136/esmoopen-2017-000222
record_format openpolar
spelling crelsevierbv:10.1136/esmoopen-2017-000222 2023-05-15T17:43:15+02:00 Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis Norum, Jan Antonsen, Margareth Aarag Tollåli, Terje Al-Shibli, Khalid Andersen, Gry Svanqvist, Kristin Helene Helbekkmo, Nina UiT- The Arctic University of Norway 2017 http://dx.doi.org/10.1136/esmoopen-2017-000222 https://api.elsevier.com/content/article/PII:S2059702920324273?httpAccept=text/xml https://api.elsevier.com/content/article/PII:S2059702920324273?httpAccept=text/plain https://syndication.highwire.org/content/doi/10.1136/esmoopen-2017-000222 en eng Elsevier BV https://www.elsevier.com/tdm/userlicense/1.0/ http://creativecommons.org/licenses/by-nc/4.0/ CC-BY-NC ESMO Open volume 2, issue 3, page e000222 ISSN 2059-7029 Cancer Research Oncology journal-article 2017 crelsevierbv https://doi.org/10.1136/esmoopen-2017-000222 2022-11-30T12:51:00Z Article in Journal/Newspaper Northern Norway ScienceDirect (Elsevier - via Crossref) Norway ESMO Open 2 3 e000222
institution Open Polar
collection ScienceDirect (Elsevier - via Crossref)
op_collection_id crelsevierbv
language English
topic Cancer Research
Oncology
spellingShingle Cancer Research
Oncology
Norum, Jan
Antonsen, Margareth Aarag
Tollåli, Terje
Al-Shibli, Khalid
Andersen, Gry
Svanqvist, Kristin Helene
Helbekkmo, Nina
Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis
topic_facet Cancer Research
Oncology
author2 UiT- The Arctic University of Norway
format Article in Journal/Newspaper
author Norum, Jan
Antonsen, Margareth Aarag
Tollåli, Terje
Al-Shibli, Khalid
Andersen, Gry
Svanqvist, Kristin Helene
Helbekkmo, Nina
author_facet Norum, Jan
Antonsen, Margareth Aarag
Tollåli, Terje
Al-Shibli, Khalid
Andersen, Gry
Svanqvist, Kristin Helene
Helbekkmo, Nina
author_sort Norum, Jan
title Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis
title_short Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis
title_full Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis
title_fullStr Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis
title_full_unstemmed Pembrolizumab as second-line therapy in non-small cell lung cancer in northern Norway: budget impact and expected gain—a model-based analysis
title_sort pembrolizumab as second-line therapy in non-small cell lung cancer in northern norway: budget impact and expected gain—a model-based analysis
publisher Elsevier BV
publishDate 2017
url http://dx.doi.org/10.1136/esmoopen-2017-000222
https://api.elsevier.com/content/article/PII:S2059702920324273?httpAccept=text/xml
https://api.elsevier.com/content/article/PII:S2059702920324273?httpAccept=text/plain
https://syndication.highwire.org/content/doi/10.1136/esmoopen-2017-000222
geographic Norway
geographic_facet Norway
genre Northern Norway
genre_facet Northern Norway
op_source ESMO Open
volume 2, issue 3, page e000222
ISSN 2059-7029
op_rights https://www.elsevier.com/tdm/userlicense/1.0/
http://creativecommons.org/licenses/by-nc/4.0/
op_rightsnorm CC-BY-NC
op_doi https://doi.org/10.1136/esmoopen-2017-000222
container_title ESMO Open
container_volume 2
container_issue 3
container_start_page e000222
_version_ 1766145272320098304